Given the importance of Lp-PLA2 as a biomarker of cardiovascular disease pathogenesis and the development of therapeutics directed at Lp-PLA2, a better understanding of how genetic variation controls Lp-PLA2 activity and mass is warranted. This evidence concerns the gene PLA2G7 and cardiovascular disorder.